Avanos Medical, Inc. (AVNS)
| Market Cap | 1.17B +109.1% |
| Revenue (ttm) | 715.90M +3.9% |
| Net Income | -74.40M |
| EPS | -1.60 |
| Shares Out | 46.85M |
| PE Ratio | n/a |
| Forward PE | 21.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,075,760 |
| Open | 24.98 |
| Previous Close | 24.98 |
| Day's Range | 24.98 - 25.00 |
| 52-Week Range | 9.30 - 25.49 |
| Beta | 1.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About AVNS
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, ... [Read more]
Financial Performance
In 2025, Avanos Medical's revenue was $701.20 million, an increase of 1.95% compared to the previous year's $687.80 million. Losses were -$72.90 million, -81.41% less than in 2024.
Financial StatementsNews
Sterlington Advises Avanos Medical Management Team on $1.27 Billion Acquisition
NEW YORK--(BUSINESS WIRE)--Sterlington advises Avanos Medical management team on $1.27 billion acquisition.
Avanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners
ALPHARETTA, Ga., July 22, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) ("Avanos" or the "Company"), a leading medical technology company, today announced that its stockholders have voted to ...
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
NEW YORK, July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600
Avanos Medical Proxy statement: Proxy filing
Avanos Medical filed a proxy statement on July 15, 2026, providing details for shareholder voting and corporate governance matters.
Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger
ALPHARETTA, Ga. and NEW YORK, July 2, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) ("Avanos") and American Industrial Partners ("AIP") jointly announced the receipt of all required regulator...
Avanos Medical Proxy statement: Proxy filing
Avanos Medical filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
Avanos Medical Proxy statement: Proxy filing
Avanos Medical filed a proxy statement on June 10, 2026, providing details for shareholder voting and corporate governance matters.
Avanos Medical Proxy statement: Proxy filing
Avanos Medical filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Avanos Medical Quarterly report: Q1 2026
Avanos Medical has published its Q1 2026 quarterly earnings report on May 5, 2026.
Avanos Medical Earnings release: Q1 2026
Avanos Medical released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Avanos Medical Proxy statement: Proxy filing
Avanos Medical filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Avanos Medical, Inc. Announces First Quarter 2026 Results
Delivered double-digit organic growth led by Specialty Nutrition Systems segment Generated $0.11 of diluted earnings per share and $0.22 of adjusted diluted earnings per share On April 14, 2026, annou...
Avanos Medical Proxy statement: Proxy filing
Avanos Medical filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
This Healthcare Stock Is Rising 69%. It's Getting Bought Out for a Big Premium.
Avanos Medical agrees to be acquired by the private-equity firm American Industrial Partners in an all-cash deal worth $1.27 billion.
Avanos Medical Proxy statement: Proxy filing
Avanos Medical filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Avanos Medical Proxy statement: Proxy filing
Avanos Medical filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
AIP to take Avanos Medical private in a deal valued at about $1.27 billion
Avanos Medical said on Tuesday it has agreed to be bought by affiliates of American Industrial Partners (AIP) in an all-cash deal worth about $1.27 billion.
Avanos Medical, Inc. Agrees To Be Acquired by American Industrial Partners for Approximately $1.272 Billion
Avanos Stockholders To Receive $25.00 Per Share in Cash ALPHARETTA, Ga. and NEW YORK, April 14, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today anno...
Avanos Medical Proxy statement: Proxy Filing
Avanos Medical filed a proxy statement on March 12, 2026, providing details for shareholder voting and corporate governance matters.
Avanos Medical Proxy statement: Proxy Filing
Avanos Medical filed a proxy statement on March 12, 2026, providing details for shareholder voting and corporate governance matters.
Avanos Medical Transcript: The Citizens Life Sciences Conference 2026
Streamlined operations and divested underperforming assets while focusing on specialty nutrition and pain management. Achieved strong 2025 results, set mid-single-digit growth targets, and outlined a path to $1 billion revenue by 2030 through organic growth and targeted acquisitions. Product innovation and tariff mitigation remain key priorities.
Avanos Medical, Inc. to Present at the 2026 Citizens Life Sciences Conference
ALPHARETTA, Ga., March 2, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Dave Pacitti, chief executive officer, and Scott Galovan, senior vice president and chief financia...
Avanos Medical, Inc. to Nominate James Cunniff and William Burke to Board of Directors
Enters into Agreement with Bradley L. Radoff ALPHARETTA, Ga.
Avanos Medical Earnings Call Transcript: Q4 2025
Delivered strong 2025 results, exceeding revised sales and earnings guidance, with robust growth in Specialty Nutrition Systems and Pain Management & Recovery. 2026 guidance anticipates continued organic growth, margin improvement in the second half, and successful tariff mitigation as China exit completes.
Avanos Medical Annual report: Q4 2025
Avanos Medical has published its Q4 2025 annual report on February 24, 2026.